Ninčević, V.;                     Omanović Kolarić, T.;                     Roguljić, H.;                     Kizivat, T.;                     Smolić, M.;                     Bilić Ćurčić, I.    
        Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. Int. J. Mol. Sci. 2019, 20, 5831.
    https://doi.org/10.3390/ijms20235831
    AMA Style
    
                                Ninčević V,                                 Omanović Kolarić T,                                 Roguljić H,                                 Kizivat T,                                 Smolić M,                                 Bilić Ćurčić I.        
                Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. International Journal of Molecular Sciences. 2019; 20(23):5831.
        https://doi.org/10.3390/ijms20235831
    
    Chicago/Turabian Style
    
                                Ninčević, Vjera,                                 Tea Omanović Kolarić,                                 Hrvoje Roguljić,                                 Tomislav Kizivat,                                 Martina Smolić,                                 and Ines Bilić Ćurčić.        
                2019. "Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes" International Journal of Molecular Sciences 20, no. 23: 5831.
        https://doi.org/10.3390/ijms20235831
    
    APA Style
    
                                Ninčević, V.,                                 Omanović Kolarić, T.,                                 Roguljić, H.,                                 Kizivat, T.,                                 Smolić, M.,                                 & Bilić Ćurčić, I.        
        
        (2019). Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. International Journal of Molecular Sciences, 20(23), 5831.
        https://doi.org/10.3390/ijms20235831